The US Food and Drug Administration has accepted for priority review the supplemental biologics license application for pembrolizumab (Keytruda) to treat patients with resectable, locally advanced ...

The FDA granted priority review to pembrolizumab for neoadjuvant and adjuvant use in head and neck squamous cell carcinoma, ...

Cover for high-cost cancer drugs, including Pembrolizumab, is subject to pre-authorisation and a case-by-case review, ...

Trial to begin enrolling in April; expected primary completion in mid-2027 -- Primary study endpoint of rate of major pathological response ...

Ignite Proteomics announced the presentation of new data demonstrating that MHC-II protein expression is a superior predictor of response to ...

Pembrolizumab provided clinical benefit in previously treated advanced clear cell gynaecological cancer (CCGC). A single-arm ...

The FDA granted breakthrough therapy status to first-line petosemtamab plus pembrolizumab for PD-L1–positive recurrent or ...

The lead investigator for EV-302 said not long ago, survival of 12 to 14 months in this type of bladder cancer was considered ...

The Odessa American is the leading source of local news, information, entertainment and sports for the Permian Basin.

PFS and OS benefits over chemotherapy were maintained for more than 2 years, and many patients had durable responses to ...

In the initial publication in 2021, the KETYNOTE-564 trial demonstrated that adjuvant pembrolizumab was associated with ...

Groundbreaking findings from the landmark CLEAR (Clinical trial Comparing Lenvatinib with Ecerolimus or Pembrolizumab in ...